Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.

Yasir Elamin,Jacqulyne P. Robichaux,Brett W. Carter,Mehmet Altan,Don L. Gibbons,Frank V. Fossella,Vincent K. Lam,Anisha B. Patel,Marcelo V. Negrao,Xiuning Le,Frank E. Mott,Jianjun Zhang,Lei Feng,George R. Blumenschein,Anne S. Tsao,John V. Heymach

Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.

2021

Yasir Elamin
Jacqulyne P. Robichaux
Brett W. Carter
Mehmet Altan
Don L. Gibbons
Frank V. Fossella
Vincent K. Lam
Anisha B. Patel
Marcelo V. Negrao
Xiuning Le
Frank E. Mott
Jianjun Zhang
Lei Feng
George R. Blumenschein
Anne S. Tsao
John V. Heymach

PURPOSETargeted therapies against non–small-cell lung cancer (NSCLC) harboring HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of poziotinib in patients with...

Keywords:

Lung cancer
MEDLINE
in patient
Oncology
Exon
non small cell
Mutant
Medicine
Poziotinib
Internal medicine
Text mining

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations